Loading…
← CockpitCompetitor Analysis › DMP.DE Dermapharm Holding SEOpen in the cockpit ↗

Dermapharm Holding SEDMP.DECompetitor analysis, valuation and peers

Germany · EUR·Health Care›Pharmaceuticals: Major

German maker of branded generic drugs, specialty pharmaceuticals and OTC health products, also producing allergy immunotherapies.

≈ A German branded-generics maker like a smaller Perrigo/AmnealMomentum laggard 19
Mkt cap
$1.85B
US dollars, full cap
Free float
3%
of shares outstanding
$/day
$960,759
20-day average traded
Fwd P/E
13.2×
forward earnings
ROIC−WACC
+5.1 pp
WACC 6.1%
Hurdle
-11 pp
Req g minus delivered
Next earnings
147 days
14 Apr 2027
Close · EUR€34.05
1D-2.7%
1W-11.8%
1M-11.0%
3M-15.2%
6M-29.1%
YTD-13.5%
1Y-3.5%
ATR %2.9%
52w lowhigh34.4% off high

What Dermapharm does

German maker of branded generic drugs, specialty pharmaceuticals and OTC health products, also producing allergy immunotherapies.

Grows largely by buying established brand-name drugs and making them in its own German plants, so it earns manufacturing margin on mature products rather than depending on new launches. The founding Beier family remains the controlling shareholder. It also filled COVID vaccine doses under contract for BioNTech.

In one line: A German branded-generics maker like a smaller Perrigo/Amneal.

Products and services

  • Branded generic drugs
  • Specialty pharmaceuticals
  • OTC/consumer health products
  • Allergy immunotherapy (Allergopharma)

Customers

  • Pharmacies
  • Physicians/prescribers
  • Consumers (OTC)

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Branded generics & specialty pharma…

What could go right

  • German generics/branded-pharma demand
  • OTC self-medication growth

What could go wrong

  • Generic drug pricing pressure
  • Regulatory/reimbursement changes

Moat: narrow (brand, regulatory licence, scale). Established branded-generic portfolio and German manufacturing base, but generics pricing is competitive.

Headquarters: Grafelfing, Germany · Founded: 1991 · Employees: 3,500

Named competitors

Dermapharm at a glance

Size Dermapharm (DMP.DE) is a Germany Health Care company (Pharmaceuticals: Major) with a market value of $1.85B, the 108th largest of 198 Germany companies the cockpit tracks. Shares closed at €34.05 on 18 Nov 2026.

Performance Over six months the shares fell 29.1%, against -4.7% for the median peer and -0.9% for the Germany market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 1.7% over the last twelve months (peer median +10.0%); the operating margin is 20.9% (peer median 12.7%).

Valuation It trades at 13.2× forward earnings against a peer median of 18.9× (8th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 5.1 points above its cost of capital (6.1% WACC).

Next results Next results expected around 14 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 97DMP.DE 70
Six months, rebased to 100: Dermapharm against the median of its 20 peers (local-currency closes).

Dermapharm financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€1.18B€1.16B€1.18B€1.14B€1.02B
Revenue growth—-1%+4%+11%—
Gross profit€399M€392M€390M€343M€370M
EBITDA€353M€314M€298M€305M€362M
Net income€130M€132M€114M€62.4M€134M
Free cash flow€151M€139M€114M€150M€247M
Capital expenditure€51.6M€42.1M€38.2M€41.5M€39.0M
Total debt€1.12B€1.05B€980M€1.08B€516M

Quarterly statements and history in the cockpit →

Dermapharm competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%-10%0%+10%000908COHANCE300573600211605507300009PFIZER000028ZYMERARE002399ALIVUS3933SHILPAMEDETON6006640512AGIO4540DMP.DE6-month return →1-month return →
Up and to the right = strong over both horizons. Dermapharm is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×COHANCE300573600211605507300009PFIZER000028ZYME3010150023993933SHILPAMEDETONDMP.DERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Dermapharm is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%300573600211000028ALIVUSETONDMP.DEGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Dermapharm is the large dot.

Dermapharm competitors and peer comparison

Head to head with its named competitors (DMP.DE vs SDZ.SW vs PRGO vs VTRS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Dermapharm DMP.DE$1.85B-29%+2%21%13.2×-3.4%
Sandoz SDZ.SW$41.7B+26%+1%15%24.5×7.5%
Perrigo PRGO$2.35B+52%-4%5%6.7×14.1%
Viatris VTRS$23.3B+23%+5%11%7.5×11.2%
Hikma Pharmaceuticals HIK.L$4.58B+15%+2%20%9.8×2.0%
Teva Pharmaceutical Industries Limited Sponsored ADR TEVA$49.3B+23%-4%19%15.0×10.5%
ALK-abello A/S ALK-B.CO$7.94B-8%+16%26%34.8×7.3%

How Dermapharm compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dermapharm against its 20 peers (data as of 18 Nov 2026)
MeasureDMP.DEPeer medianRank in peer set
1-month return-11.0%+0.7%4th lowest of 21
6-month return-29.1%-4.7%2nd lowest of 21
Distance from 52-week high-34.4%-28.3%8th lowest of 21
Revenue growth (TTM)+1.7%+10.0%6th lowest of 21
Operating margin20.9%12.7%7th highest of 21
Forward P/E13.2×18.9×8th cheapest of 19
Growth the price implies (Req g, 7 yrs)-3.4%1.2%4th least demanding of 14
Growth delivered (Del g)+8.0%+7.8%7th highest of 14
Hurdle (Req g minus delivered)-11.4 pp-12.8 pp7th most demanding of 14
ROIC minus cost of capital+5.1 pp+0.7 pp9th highest of 21
EV / EBITDA7.6×18.2×2nd cheapest of 10
Net debt / EBITDA2.8×0.7×2nd most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Shenzhen Hepalink Pharmaceutical 002399.SZChina$1.80B-12%-6%8%25.8×-0.7%+0.5%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a

Questions

Who are Dermapharm's main competitors?
Named competitors: Sandoz (Hexal) (SDZ.SW), Perrigo (PRGO), Stada Arzneimittel (private) (private or unlisted), Viatris (VTRS), Hikma Pharmaceuticals (HIK.L), Teva Pharmaceutical (TEVA). The cockpit's measured peer set (industry) also includes CSPC Hunan Jingfeng Pharmaceutical (000908.SZ), Cohance Lifesciences (COHANCE.NS), Shenyang Xingqi Pharmaceutical (300573.SZ), Tibet Rhodiola Pharmaceutical (600211.SS), Guobang Pharma (605507.SS), Anhui Anke Biotechnology (Group) (300009.SZ).
Is Dermapharm expensive compared with its peers?
On forward p/e it trades at 13.2× against a peer median of 18.9×, 8th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -3% a year for seven years (Req g). Recent delivered growth is +8%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has Dermapharm stock performed?
Over six months to 18 Nov 2026 the shares returned -29.1% against -4.7% for the median peer; over one year -3.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.